Aeon Biopharma Inc (AEON) Stock Price, Quote & News

Company Profile

AEON Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on developing botulinum toxins. It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed Phase 2 study for the treatment of cervical dystonia and has an ongoing Phase 2 study for the treatment of chronic and episodic migraine. It also develops ABP-450 for the treatment of gastroparesis and post-traumatic stress disorder. The company has license agreements Daewoong Pharmaceutic...

Industry: Biotechnology

Sector: Healthcare

Phone: 949 354 6499

Website: www.aeonbiopharma.com

Address:

5 Park Plaza, Suite 1750, Irvine, United States

CyrusTrade Jul. 15 at 10:02 PM

$AEON will be pinned to 0.30 and every pop will be directly shorted by unlimited number of shares and warrants. The RS will push it down another 50%

0 · Reply

Makingmillions192 Jul. 15 at 1:11 PM

$LEXX Way oversold and due for a nice melt-up with data drops starting in Aug ⏰ $HYMC $AEON $SHPH

1 · Reply

VXRT007 Jul. 15 at 1:41 AM

$AEON This company fucked around with pumping up and down and ran out of money at the 1.09 deal mark. Look for yourself. Now they pull this one. I dont normally like that word scam but I do think the company is a POS.

0 · Reply

TheBlackBerrry Jul. 14 at 10:11 PM

$XCUR $IBM $GMEX $AEON $BATL They removed pdt so they can steal your pdt account monthly, on the sly

1 · Reply

Donniechen12345 Jul. 14 at 9:42 PM

$AEON lmao dilution machine scaming $40 million with a $7 million market cap hahaha lol .,,, this trash company will drop below .05 cents soon in 1 month lol , then follow by a reversed split 1-100 LOL , seen this movie all the times hahahah . stay away !!!!!!!

0 · Reply

TheUnmaker Jul. 14 at 8:50 PM

$XCUR take it to $AEON You'll get a better pump there and safer entry since its bottomed out

0 · Reply

TheUnmaker Jul. 14 at 8:42 PM

$XCUR Slide in to $AEON

0 · Reply

topstockalerts Jul. 14 at 7:50 PM

$AEON nice little move developing… could build from here

0 · Reply

TradeX_ Jul. 14 at 7:50 PM

Looks like BMGL might be the next 800% runner. Crazy market! Every micro float ticker has been going parabolic this month. Would not be surprised if they send BMGL up now. BMGL starting to make its move now! Only 750k shares outstanding! 💎 $MARA $AEON $JOBY $NXTC cx

0 · Reply

rayankhader Jul. 14 at 7:49 PM

$AEON $VIVK still waiting on you 👀💎🏦 $VMAR $SHPH profit secure this morning

0 · Reply

Aeon announces pricing of upsized $13.75M public offering

Jul 14, 2026, 8:00 AM EDT - 2 days ago

AEON Biopharma Announces Pricing of Upsized $13.75 Million Public Offering with Accompanying Milestone Warrants Providing Potential for Additional Future Funding

Jul 9, 2026, 8:00 AM EDT - 7 days ago

AEON Biopharma Registration statement: Registration filing

Jul 8, 2026, 8:00 AM EDT - 8 days ago

AEON Biopharma Registration statement: Registration filing

Jun 4, 2026, 7:00 AM EDT - 6 weeks ago

AEON Biopharma to Present Data Demonstrating Structural and Functional Comparability of ABP-450 to BOTOX® at the 68th Annual Scientific Meeting of the American Headache Society

May 14, 2026, 4:05 PM EDT - 2 months ago

AEON Biopharma Reports First Quarter 2026 Financial Results and Provides Corporate Update

May 14, 2026, 4:00 PM EDT - 2 months ago

AEON Biopharma Earnings release: Q1 2026

May 14, 2026, 4:00 PM EDT - 2 months ago

AEON Biopharma Quarterly report: Q1 2026

2026-05-14T14:19:48.000Z - 2 months ago

Aeon Biopharma management to meet virtually with Lake Street

May 14, 2026, 7:00 AM EDT - 2 months ago

AEON Biopharma Slides: Corporate presentation

Apr 29, 2026, 8:00 AM EDT - 2 months ago

AEON Biopharma Proxy statement: Proxy filing

Apr 29, 2026, 8:00 AM EDT - 2 months ago

AEON Biopharma Proxy statement: Proxy filing

Apr 24, 2026, 4:05 PM EDT - 2 months ago

AEON Biopharma Sets Annual Shareholder Meeting

2026-04-06T01:20:06.000Z - 3 months ago

Aeon receives additional notice related to NYSE American listing standards

Apr 3, 2026, 4:10 PM EDT - 3 months ago

AEON Biopharma Reports Inducement Grants Under NYSE American LLC Company Guide Section 711

Apr 3, 2026, 4:05 PM EDT - 3 months ago

AEON Biopharma Receives Additional Notice Related to NYSE American Continued Listing Standards

Mar 30, 2026, 4:05 PM EDT - 3 months ago

AEON Biopharma Reports Full Year 2025 Financial Results and Highlights Positive Comparative Analytical Results and FDA Feedback for ABP-450 Biosimilar Program

Mar 30, 2026, 4:00 PM EDT - 3 months ago

AEON Biopharma Annual report: Q4 2025

Mar 30, 2026, 4:00 PM EDT - 3 months ago

AEON Biopharma Earnings release: Q4 2025

2026-03-25T12:17:47.000Z - 4 months ago

Aeon Biopharma announces FDA feedback after Type 2a meeting

2026-03-09T20:45:55.000Z - 4 months ago

Aeon Biopharma appoints John Bencich as CFO

ACHV

2026-02-09T21:45:15.000Z - 5 months ago

Aeon Biopharma files to sell 51.29M shares of Class A common stock for holders

Feb 9, 2026, 7:00 AM EST - 5 months ago

AEON Biopharma Registration statement: Registration Filing

Jan 22, 2026, 7:00 AM EST - 6 months ago

AEON Biopharma Slides: Corporate presentation

2026-01-21T21:25:21.000Z - 6 months ago

Aeon Biopharma reports BPD Type 2a meeting with FDA

Jan 21, 2026, 4:05 PM EST - 6 months ago

AEON Biopharma Reports BPD Type 2a Meeting with FDA and Shareholder Approval of the November Transactions

Dec 29, 2025, 7:00 AM EST - 7 months ago

AEON Biopharma Proxy statement: Proxy Filing

Dec 19, 2025, 7:00 AM EST - 7 months ago

AEON Biopharma Proxy statement: Proxy Filing

Dec 15, 2025, 4:05 PM EST - 7 months ago

AEON Biopharma Announces Execution of Exchange Agreement with Daewoong

2025-11-20T13:46:22.000Z - 8 months ago

Aeon Biopharma announces rescheduling of BPD Type 2a meeting with FDA

Nov 20, 2025, 8:30 AM EST - 8 months ago

AEON Biopharma Announces First Closing of PIPE Investment and Provides Update on FDA Type 2a Meeting Scheduling

2025-11-14T13:35:33.000Z - 8 months ago

Aeon Biopharma reports Q3 EPS (39c) vs ($11.24) last year

Nov 14, 2025, 8:30 AM EST - 8 months ago

AEON Biopharma Reports Third Quarter 2025 Results, Including Positive ABP-450 Biosimilarity Data and Strategic Positioning for Continued Growth

Nov 14, 2025, 8:30 AM EST - 8 months ago

AEON Biopharma Quarterly report: Q3 2025

Nov 14, 2025, 8:30 AM EST - 8 months ago

AEON Biopharma Earnings release: Q3 2025

Nov 14, 2025, 7:00 AM EST - 8 months ago

AEON Biopharma Proxy statement: Proxy Filing

Nov 13, 2025, 8:30 AM EST - 8 months ago

AEON Biopharma Announces Fundraise Totaling Up to ~$22 Million through Private Placement and Proposed Exchange of Daewoong Convertible Notes

Nov 13, 2025, 7:00 AM EST - 8 months ago

AEON Biopharma Proxy statement: Proxy Filing

2025-10-01T12:20:41.000Z - 10 months ago

Aeon Biopharma announces FDA BPD Type 2a meeting for ABP-450

Oct 1, 2025, 8:00 AM EDT - 10 months ago

AEON Biopharma Announces FDA BPD Type 2a Meeting for ABP-450 on November 19

Aug 12, 2025, 4:05 PM EDT - 1 year ago

AEON Biopharma Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Aug 12, 2025, 4:00 PM EDT - 1 year ago

AEON Biopharma Quarterly report: Q2 2025

Aug 12, 2025, 4:00 PM EDT - 1 year ago

AEON Biopharma Earnings release: Q2 2025

Jun 11, 2025, 8:00 AM EDT - 1 year ago

AEON Biopharma Proxy statement: Proxy Filing

May 19, 2025, 4:05 PM EDT - 1 year ago

AEON Biopharma to Present at the Aegis Capital Corp. Virtual Conference 2025

May 14, 2025, 4:05 PM EDT - 1 year ago

AEON Biopharma Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 14, 2025, 4:00 PM EDT - 1 year ago

AEON Biopharma Earnings release: Q1 2025

May 14, 2025, 4:00 PM EDT - 1 year ago

AEON Biopharma Quarterly report: Q1 2025

Apr 29, 2025, 8:00 AM EDT - 1 year ago

AEON Biopharma Proxy statement: Proxy Filing

Apr 25, 2025, 4:05 PM EDT - 1 year ago

AEON Biopharma Announces NYSE American Acceptance of Plan to Regain Listing Compliance

2025-04-21T20:16:30.000Z - 1 year ago

Aeon Biopharma appoints Rob Bancroft as CEO

Apr 21, 2025, 4:05 PM EDT - 1 year ago

AEON Biopharma Appoints Industry Veteran Rob Bancroft as Chief Executive Officer

Mar 27, 2025, 4:05 PM EDT - 1 year ago

AEON Biopharma Announces CEO Transition

Mar 24, 2025, 4:05 PM EDT - 1 year ago

AEON Biopharma Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

Mar 24, 2025, 9:00 AM EDT - 1 year ago

AEON Biopharma Annual report: Q4 2024

Mar 24, 2025, 9:00 AM EDT - 1 year ago

AEON Biopharma Earnings release: Q4 2024

Mar 4, 2025, 8:00 AM EST - 1 year ago

AEON Biopharma, Inc. to Participate in the Leerink Global Healthcare Conference

Feb 24, 2025, 2:00 PM EST - 1 year ago

AEON Biopharma, Inc. Announces Reverse Stock Split

Feb 7, 2025, 4:05 PM EST - 1 year ago

AEON Biopharma, Inc. Receives Notice of Non-Compliance with NYSE American Continued Listing Standards

Jan 23, 2025, 7:00 AM EST - 1 year ago

AEON Biopharma Proxy statement: Proxy Filing

Jan 13, 2025, 7:00 AM EST - 1 year ago

AEON Biopharma Proxy statement: Proxy Filing

Jan 7, 2025, 9:37 AM EST - 1 year ago

AEON Biopharma, Inc. Announces Closing of $20.0 Million Underwritten Public Offering

2025-01-06T14:15:17.000Z - 1 year ago

Aeon Biopharma prices 40M units at 50c in underwritten public offering

Jan 3, 2025, 8:02 PM EST - 1 year ago

AEON Biopharma, Inc. Announces Launch of Proposed Public Offering

Nov 13, 2024, 4:05 PM EST - 1 year ago

AEON Biopharma Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Nov 13, 2024, 7:00 AM EST - 1 year ago

AEON Biopharma Quarterly report: Q3 2024

Nov 13, 2024, 7:00 AM EST - 1 year ago

AEON Biopharma Earnings release: Q3 2024

2024-09-30T12:11:48.000Z - 1 year ago

Aeon Biopharma announces outcome from FDA biosimilar advisory meeting

Aug 19, 2024, 4:05 PM EDT - 2 years ago

AEON Biopharma to Participate in the H.C. Wainwright 26th Annual Global Investment Conference 2024

Aug 15, 2024, 8:00 AM EDT - 2 years ago

AEON Biopharma Registration statement: Registration Filing

2024-08-15T10:13:15.000Z - 2 years ago

Aeon Biopharma files $200M mixed securities shelf

2024-08-14T10:11:02.000Z - 2 years ago

Aeon Biopharma price target lowered to $5 from $6 at H.C. Wainwright

Aug 12, 2024, 4:05 PM EDT - 2 years ago

AEON Biopharma Reports Second Quarter 2024 Financial Results and Provides Corporate Update

Aug 12, 2024, 7:00 AM EDT - 2 years ago

AEON Biopharma Quarterly report: Q2 2024

Aug 12, 2024, 7:00 AM EDT - 2 years ago

AEON Biopharma Earnings release: Q2 2024

Jul 23, 2024, 8:00 AM EDT - 2 years ago

AEON Biopharma Registration statement: Registration Filing

May 31, 2024, 8:00 AM EDT - 2 years ago

AEON Biopharma Registration statement: Registration Filing

2024-05-29T12:12:33.000Z - 2 years ago

Aeon Biopharma discontinues Phase 2 study of ABP-450 in chronic migraine

May 29, 2024, 8:00 AM EDT - 2 years ago

AEON Biopharma Announces Strategic Resource Reprioritization and Cost Reduction Plan

May 14, 2024, 4:05 PM EDT - 2 years ago

AEON Biopharma Reports First Quarter 2024 Financial Results

May 14, 2024, 8:00 AM EDT - 2 years ago

AEON Biopharma Proxy statement: Proxy Filing

May 14, 2024, 7:00 AM EDT - 2 years ago

AEON Biopharma Quarterly report: Q1 2024

May 14, 2024, 7:00 AM EDT - 2 years ago

AEON Biopharma Earnings release: Q1 2024

May 9, 2024, 8:00 AM EDT - 2 years ago

AEON Biopharma Provides Update on Development Pipeline

May 3, 2024, 7:00 AM EDT - 2 years ago

AEON Biopharma Announces Preliminary Top-Line Results from Phase 2 Interim Analysis of ABP-450 in the Preventive Treatment of Chronic Migraine

Apr 29, 2024, 8:00 AM EDT - 2 years ago

AEON Biopharma Proxy statement: Proxy Filing

Apr 17, 2024, 8:00 AM EDT - 2 years ago

AEON Biopharma Proxy statement: Proxy Filing

Apr 2, 2024, 8:00 AM EDT - 2 years ago

AEON Biopharma Registration statement: Registration Filing

Mar 30, 2024, 10:53 PM EDT - 2 years ago

CORRECTION -- AEON Biopharma Announces Redemption of Public Warrants

Mar 29, 2024, 4:15 PM EDT - 2 years ago

AEON Biopharma Announces Redemption of Public Warrants

Mar 29, 2024, 3:45 PM EDT - 2 years ago

AEON Biopharma Reports Fourth Quarter and Full Year 2023 Financial Results

Mar 29, 2024, 8:00 AM EDT - 2 years ago

AEON Biopharma Annual report: Q4 2023

Mar 29, 2024, 8:00 AM EDT - 2 years ago

AEON Biopharma Earnings release: Q4 2023

Mar 19, 2024, 4:30 PM EDT - 2 years ago

AEON Biopharma Announces Clinical Update and Productive End-of-Phase 2 Meeting with FDA on ABP-450 (prabotulinumtoxinA) for the Preventive Treatment of Migraine

Mar 19, 2024, 4:29 PM EDT - 2 years ago

AEON Biopharma Announces $15 Million Financing Transaction and Termination of Forward Purchase Agreements

Jan 18, 2024, 4:05 PM EST - 2 years ago

AEON Biopharma Presents Positive Clinical and Pre-clinical Data for ABP-450 (prabotulinumtoxinA) in Treating Cervical Dystonia and PTSD, Respectively, at a Leading Neurotoxin Conference

Dec 12, 2023, 8:00 AM EST - 2 years ago

AEON Biopharma Completes Enrollment in Phase 2 Study of ABP-450 (prabotulinumtoxinA) for Preventive Treatment of Chronic Migraine

Nov 24, 2023, 7:00 AM EST - 2 years ago

AEON Biopharma Registration statement: Registration Filing

Nov 13, 2023, 8:15 AM EST - 2 years ago

AEON Biopharma Reports Third Quarter 2023 Financial Results

Nov 13, 2023, 7:00 AM EST - 2 years ago

AEON Biopharma Quarterly report: Q3 2023

Nov 13, 2023, 7:00 AM EST - 2 years ago

AEON Biopharma Earnings release: Q3 2023

Oct 23, 2023, 8:00 AM EDT - 2 years ago

AEON Biopharma Registration statement: Registration Filing

Oct 19, 2023, 4:05 PM EDT - 2 years ago

AEON Biopharma Announces Topline Results from Phase 2 Trial of ABP-450 (prabotulinumtoxinA) for the Preventive Treatment of Episodic Migraine

Aug 29, 2023, 8:00 AM EDT - 3 years ago

AEON Biopharma Presents Positive Results from Phase 2 Clinical Trial of ABP-450 (prabotulinumtoxinA) in Cervical Dystonia at the International Parkinson and Movement Disorders Society Congress®

Aug 24, 2023, 8:00 AM EDT - 3 years ago

AEON Biopharma Receives Notice of Allowance from USPTO for a Patent Covering Use of Botulinum Toxins to Treat Migraine Headache

Aug 18, 2023, 8:00 AM EDT - 3 years ago

AEON Biopharma Registration statement: Registration Filing

Aug 16, 2023, 7:00 AM EDT - 3 years ago

Strathspey Crown Holdings Group, LLC Provides Clarifying Statement Regarding Form 4 Filing with SEC for Holdings in AEON Biopharma

Jul 24, 2023, 7:00 AM EDT - 3 years ago

AEON Biopharma Announces Closing of Business Combination with Priveterra Acquisition Corp. and Provides Pipeline Update

CyrusTrade Jul. 15 at 10:02 PM

$AEON will be pinned to 0.30 and every pop will be directly shorted by unlimited number of shares and warrants. The RS will push it down another 50%

0 · Reply

Makingmillions192 Jul. 15 at 1:11 PM

$LEXX Way oversold and due for a nice melt-up with data drops starting in Aug ⏰ $HYMC $AEON $SHPH

1 · Reply

VXRT007 Jul. 15 at 1:41 AM

0 · Reply

TheBlackBerrry Jul. 14 at 10:11 PM

$XCUR $IBM $GMEX $AEON $BATL They removed pdt so they can steal your pdt account monthly, on the sly

1 · Reply

Donniechen12345 Jul. 14 at 9:42 PM

0 · Reply

TheUnmaker Jul. 14 at 8:50 PM

$XCUR take it to $AEON You'll get a better pump there and safer entry since its bottomed out

0 · Reply

TheUnmaker Jul. 14 at 8:42 PM

$XCUR Slide in to $AEON

0 · Reply

topstockalerts Jul. 14 at 7:50 PM

$AEON nice little move developing… could build from here

0 · Reply

TradeX_ Jul. 14 at 7:50 PM

0 · Reply

rayankhader Jul. 14 at 7:49 PM

$AEON $VIVK still waiting on you 👀💎🏦 $VMAR $SHPH profit secure this morning

0 · Reply

rayankhader Jul. 14 at 7:14 PM

$AEON bough this morning at .28 still holding waiting for .40👀

0 · Reply

adaptnow Jul. 14 at 3:37 PM

$AEON Lake Street’s reputation matters This is where I think the market may be underappreciating the significance. Lake Street isn’t infallible, and its involvement is not a guarantee of success. However, its reputation depends on placing offerings with institutional clients that expect serious diligence. If Lake Street believed: * management lacked credibility, * the FDA strategy was implausible, or * the asset had no realistic path forward, it would have been much harder to expand the offering. Will be watching closely to see if C suite and Directors demonstrate conviction by purchasing shares on the open market at prices below the offering.

0 · Reply

adaptnow Jul. 14 at 3:30 PM

$AEON The offering was upsized suggesting a positive objective signal. Management didn’t struggle to fill the book, they increased the size of the financing. In biotech, that’s meaningful because institutional investors had every opportunity to say: “We’ll take less.” Instead, the company raised more than initially planned. That suggests the demand curve was stronger than management initially expected. The structure is more sophisticated than a desperation financing This wasn’t simply: “Issue as many shares as possible at whatever price.” Instead, the deal includes milestone-based warrants that provide additional capital if the company creates value. That aligns incentives better than a structure designed solely to maximize immediate dilution. It suggests investors are underwriting future execution, not just buying deeply discounted shares.

0 · Reply

adaptnow Jul. 14 at 3:28 PM

$AEON Today’s financing suggests that investors with the resources to perform meaningful diligence concluded that the expected value of ABP-450 and AEON’s strategic position exceeds what was reflected in the pre-financing market price. Sophisticated capital was willing to substantially recapitalize AEON after performing due diligence on an asset that most of the public market had effectively written off.

0 · Reply

EquityVoyager_1 Jul. 14 at 2:33 PM

JULY 14, 2026 | PREMARKET STOCKS TO WATCH Early movers are on the radar as traders prepare for today’s session. These names are worth keeping an eye on before the opening bell: Top Premarket Watchlist: $VMAR $PMI $AEON $SHPH $BJDX Momentum, volume, and key price levels will decide which names attract the most attention today. Stay focused - the biggest moves often start before the market opens.

0 · Reply

ZeebraNotZebra Jul. 14 at 2:30 PM

$AEON will buy if it drops below $0.23

0 · Reply

adaptnow Jul. 14 at 1:58 PM

$AEON The milestone warrants are interesting Rather than issuing all of the shares today, AEON attached milestone warrants. This means additional capital only comes in if certain milestones are achieved and investors choose to exercise. That’s generally a more shareholder-friendly structure than issuing all the dilution immediately. Institutional investors likely participated Because this was an underwritten offering, investment banks found buyers before pricing. That suggests there were sophisticated investors willing to fund AEON despite the risks. It doesn’t guarantee success, but it is usually more encouraging than an emergency “death spiral” financing.

0 · Reply

adaptnow Jul. 14 at 1:56 PM

$AEON That is a very large issuance relative to AEON’s previous share count, so existing shareholders are diluted significantly. However, there is an important distinction: * Dilution to fund a viable asset can create value. * Dilution simply to keep the lights on usually destroys value.

0 · Reply

adaptnow Jul. 14 at 1:56 PM

$AEON This is the announcement we were waiting for. Overall, I view it as meaningfully better than a last-minute survival financing, although it comes with significant dilution. Here are the key takeaways. 1. They successfully raised capital The company priced an underwritten public offering for $13.75 million immediately, with milestone warrants that could bring the total funding to approximately $43.3 million if exercised. That accomplishes several things: * Removes the immediate cash crisis. * Greatly improves the likelihood of remaining listed. * Gives management time to execute the regulatory strategy for ABP-450. This is a much better outcome than failing to raise money. 2. The dilution is substantial The offering consists of roughly 42.7 million new shares.

0 · Reply

Donniechen12345 Jul. 14 at 1:28 PM

$AEON lmao up 50% lmao , wilmshort more at the open !$$$$$$ and dead cat bounces , this pig is done :)$$$$$$$$ .50 short avg now :)))

0 · Reply

Olivia_Strickland Jul. 14 at 1:27 PM

$AEON puking 26% premarket to .358 on 35M shares, knifing well under yesterday's .32... wait, .32 close but trading .358? that's above prior close, tape's showing me a green number on a red move. reloading before I trust any of this. live premarket tape: https://tapeboard.com/go/st/research/AEON?utm_source=stocktwits&utm_medium=post&utm_campaign=olivia&utm_content=aeon-pm-dn-tape&utm_term=research

0 · Reply

PSM_EmpowerTrading Jul. 14 at 1:22 PM

🌅📈 Watchlist part 2 ✅ $AEON low .20 support, if above .30, have potential to .40/.50 ✅ $GMEX low 1.70 support, if above 2, have potential to 2.30/2.50, high 2.73. Congrats if you got in during the swing accumulation phase below 1.20. ✅ $VIVK .30 support, if above .50, have potential to .60/.80 ✅ $SGLY low .20 support, if above .30, have potential to .40/.50 💰✅ Ideal long entry near low current support 🛡️🎯 Ideal stop loss if below current support 🚨🚫 Avoid chasing long into strength near resistance 🎯🎯 Goal is GREEN 🤑🤑, not GREED 🥵🥵

0 · Reply

Market Cap	7.58M
Revenue (ttm)	0.00
Net Income (ttm)	-39.22M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	930,600
Avg Vol	1,365,952
Day's Range	N/A - N/A
Shares Out	25.30M
Stochastic %K	8%
Beta	0.61
Analysts	Strong Sell
Price Target	$6.70